California-based clinical-stage biopharmaceutical company Kyverna Therapeutics, Inc. (Nasdaq: KYTX) announced on Monday that it has named Warner Biddle as its new chief executive officer (CEO) and member of its board of directors, succeeding Peter Maag, Ph.D., effective immediately.
Biddle brings over 30 years of global pharmaceutical leadership, most recently serving as senior vice president, global head of Commercial at Kite Pharma. At Kite, he oversaw key product launches and market growth for Yescarta and Tecartus, solidifying the company's position in cell therapy. In 2023, Biddle also served as interim head of Kite, managing key operational functions.
Previously, Biddle held leadership roles at Genentech, Novartis and GlaxoSmithKline working in Canada, the United Kingdom and Switzerland.
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business
Insmed receives highest ranking in Science's 2024 Top Employers Survey
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
Viatris added to Forbes' World's Best Employers 2024 list
Rarity Health named finalist for 21st MM+M Rare Disease Agency of the Year